Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials.

ABSTRACT:

Background

The nucleotide analogue prodrug remdesivir was among the first antiviral therapies to be tested in randomized controlled trials (RCTs) for COVID-19. We performed a meta-analysis to understand efficacy and safety.

Methods

We searched PubMed, EMBASE, Cochrane library, and ClinicalTrials.gov databases (from January 1, 2020 to November 5, 2020). We included RCTs comparing the efficacy and safety of remdesivir to control/placebo in COVID-19. Two independent investigators abstracted data, assessed the quality of evidence, and rated the certainty of evidence.

Results

A total of 4 RCTs with 7334 patients with COVID-19 were included. At a follow-up of 28-29 days from randomization, very low certainty evidence showed that use of remdesivir compared with control group

SUBMITTER: Al-Abdouh A 

PROVIDER: S-EPMC7789823 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature